News

Fructose sweeteners drive metabolic dysregulation

Publish date: March 25, 2013

 

AT THE ADA ADVANCED POSTGRADUATE COURSE

Dr. Stanhope reported having no financial disclosures.

Pages

Recommended Reading

HDL-raising: A good hypothesis gone bad
MDedge Internal Medicine
FDA approves alogliptin, alone and in combinations
MDedge Internal Medicine
Statins may reduce mortality in hepatocellular cancer
MDedge Internal Medicine
FDA withholds insulin degludec approval; wants safety data
MDedge Internal Medicine
Critics dub JNC-8 as 'JNC-Late'
MDedge Internal Medicine
Everolimus approval now includes prevention of liver transplant rejection
MDedge Internal Medicine
TERISA targets diabetes as potential new market for ranolazine
MDedge Internal Medicine
Intense statin therapy treats atheromas in diabetes
MDedge Internal Medicine
Lipid metabolism genes linked to breast cancer subtype
MDedge Internal Medicine
Being postmenopausal doubles hepatic steatosis risk
MDedge Internal Medicine